80 related articles for article (PubMed ID: 23171033)
1. Ca(2+) enhances Aβ polymerization rate and fibrillar stability in a dynamic manner.
Brännström K; Ohman A; Lindhagen-Persson M; Olofsson A
Biochem J; 2013 Feb; 450(1):189-97. PubMed ID: 23171033
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response to fibrillar beta-amyloid peptide.
Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
[TBL] [Abstract][Full Text] [Related]
3. Structural, morphological, and kinetic studies of β-amyloid peptide aggregation on self-assembled monolayers.
Wang Q; Shah N; Zhao J; Wang C; Zhao C; Liu L; Li L; Zhou F; Zheng J
Phys Chem Chem Phys; 2011 Sep; 13(33):15200-10. PubMed ID: 21769359
[TBL] [Abstract][Full Text] [Related]
4. Lysophosphatidylcholine modulates fibril formation of amyloid beta peptide.
Sheikh AM; Nagai A
FEBS J; 2011 Feb; 278(4):634-42. PubMed ID: 21205198
[TBL] [Abstract][Full Text] [Related]
5. Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation.
Bieschke J; Zhang Q; Powers ET; Lerner RA; Kelly JW
Biochemistry; 2005 Apr; 44(13):4977-83. PubMed ID: 15794636
[TBL] [Abstract][Full Text] [Related]
6. Characterization of early stage intermediates in the nucleation phase of Aβ aggregation.
Zhai J; Lee TH; Small DH; Aguilar MI
Biochemistry; 2012 Feb; 51(6):1070-8. PubMed ID: 22283417
[TBL] [Abstract][Full Text] [Related]
7. In vitro oligomerization and fibrillogenesis of amyloid-beta peptides.
Benseny-Cases N; Klementieva O; Cladera J
Subcell Biochem; 2012; 65():53-74. PubMed ID: 23224999
[TBL] [Abstract][Full Text] [Related]
8. Amide solvent protection analysis demonstrates that amyloid-beta(1-40) and amyloid-beta(1-42) form different fibrillar structures under identical conditions.
Olofsson A; Lindhagen-Persson M; Sauer-Eriksson AE; Ohman A
Biochem J; 2007 May; 404(1):63-70. PubMed ID: 17280549
[TBL] [Abstract][Full Text] [Related]
9. Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic Aβ(1-42) peptide, synthesized by depsi-peptide technique.
Stravalaci M; Beeg M; Salmona M; Gobbi M
Biosens Bioelectron; 2011 Jan; 26(5):2772-5. PubMed ID: 21112205
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics simulations of Aβ fibril interactions with β-sheet breaker peptides.
Bruce NJ; Chen D; Dastidar SG; Marks GE; Schein CH; Bryce RA
Peptides; 2010 Nov; 31(11):2100-8. PubMed ID: 20691234
[TBL] [Abstract][Full Text] [Related]
11. The N-terminal region of amyloid β controls the aggregation rate and fibril stability at low pH through a gain of function mechanism.
Brännström K; Öhman A; Nilsson L; Pihl M; Sandblad L; Olofsson A
J Am Chem Soc; 2014 Aug; 136(31):10956-64. PubMed ID: 25014209
[TBL] [Abstract][Full Text] [Related]
12. Aβ peptide fibrillar architectures controlled by conformational constraints of the monomer.
Brännström K; Ohman A; Olofsson A
PLoS One; 2011; 6(9):e25157. PubMed ID: 21980388
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's disease amyloid β-protein mutations and deletions that define neuronal binding/internalization as early stage nonfibrillar/fibrillar aggregates and late stage fibrils.
Poduslo JF; Howell KG; Olson NC; Ramirez-Alvarado M; Kandimalla KK
Biochemistry; 2012 May; 51(19):3993-4003. PubMed ID: 22545812
[TBL] [Abstract][Full Text] [Related]
14. Folding stability of amyloid-beta 40 monomer is an important determinant of the nucleation kinetics in fibrillization.
Ni CL; Shi HP; Yu HM; Chang YC; Chen YR
FASEB J; 2011 Apr; 25(4):1390-401. PubMed ID: 21209058
[TBL] [Abstract][Full Text] [Related]
15. The synaptic protein neuroligin-1 interacts with the amyloid β-peptide. Is there a role in Alzheimer's disease?
Dinamarca MC; Weinstein D; Monasterio O; Inestrosa NC
Biochemistry; 2011 Sep; 50(38):8127-37. PubMed ID: 21838267
[TBL] [Abstract][Full Text] [Related]
16. Substituted tryptophans at amyloid-β(1-40) residues 19 and 20 experience different environments after fibril formation.
McDonough RT; Paranjape G; Gallazzi F; Nichols MR
Arch Biochem Biophys; 2011 Oct; 514(1-2):27-32. PubMed ID: 21843498
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of inhibition at multiple stages of amyloid-beta self-assembly provides mechanistic insight.
Davis TJ; Soto-Ortega DD; Kotarek JA; Gonzalez-Velasquez FJ; Sivakumar K; Wu L; Wang Q; Moss MA
Mol Pharmacol; 2009 Aug; 76(2):405-13. PubMed ID: 19483107
[TBL] [Abstract][Full Text] [Related]
18. PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease.
Brambilla D; Verpillot R; Le Droumaguet B; Nicolas J; Taverna M; Kóňa J; Lettiero B; Hashemi SH; De Kimpe L; Canovi M; Gobbi M; Nicolas V; Scheper W; Moghimi SM; Tvaroška I; Couvreur P; Andrieux K
ACS Nano; 2012 Jul; 6(7):5897-908. PubMed ID: 22686577
[TBL] [Abstract][Full Text] [Related]
19. Molecular dynamics simulations of low-ordered alzheimer β-amyloid oligomers from dimer to hexamer on self-assembled monolayers.
Zhao J; Wang Q; Liang G; Zheng J
Langmuir; 2011 Dec; 27(24):14876-87. PubMed ID: 22077332
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of ferrocenoyl pentapeptide (Fc-KLVFF) as an inhibitor of Alzheimer's Aβ₁-₄₂ fibril formation in vitro.
Wei CW; Peng Y; Zhang L; Huang Q; Cheng M; Liu YN; Li J
Bioorg Med Chem Lett; 2011 Oct; 21(19):5818-21. PubMed ID: 21855336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
